RLMD News and Press, Relmada Therapeutics Inc.

2024-05-10 07:13:10 ET Relmada Therapeutics, Inc. (RLMD) Q1 2024 Earnings Conference Call May 08, 2024, 04:30 PM ET Company Participants Tim McCarthy - IR, LifeSci Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer ...

2024-05-09 12:41:10 ET More on Relmada Therapeutics Relmada Therapeutics: Run Up Into Results May Resume Following This Drop Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Relmada Therapeutics Histori...

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results PR Newswire CORAL GABLES, Fla. , May 8, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the cent...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 PR Newswire CORAL GABLES, Fla. , May 6, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addr...

2024-03-21 18:57:54 ET Summary RLMD plans to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2 2024. The current timeline for completion of enrolment in Reliance II may suggest a slight slippage, but my p...

2024-03-20 12:25:51 ET More on Mid-day movers & stocks. Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript Personalis Q4 2023 Earnings Preview XTI Aircraft that will merge with Inpixon gets Chinese patent for an aircraft Seeking Alpha’s Quant...

2024-03-19 19:08:05 ET Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Conference Call March 19, 2024, 04:30 PM ET Company Participants Tim McCarthy - IR, Advisors Sergio Traversa - CEO Maged Shenouda - CFO Conference Call Participants Basma Radwan...

2024-03-19 16:22:18 ET More on Relmada Therapeutics Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark Seeking Alpha’s Quant Rating on Relmada Therapeutics Historical earnings data for Relmada Therapeutics Financial information for Relmada Ther...

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results PR Newswire CORAL GABLES, Fla. , March 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addre...